Factors influencing short-term re-admission and one-year mortality in patients with chronic obstructive pulmonary disease

Respirology

Volumn 12, Issue 4, 2007, Pages 560-565

  Liu, Shih Feng ^a   Lin, Kuan Chun ^a   Chin, Chien Hung ^a   Chen, Yung Che ^a   Chang, Hsueh Wen ^b   Wang, Chih Chou ^a   Lin, Meng Chih ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

COPD; FEV1; Mortality; Oral steroid use; Short term re admission

Indexed keywords

CORTICOSTEROID; STEROID 11BETA MONOOXYGENASE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; PATIENT READMISSION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY;

EID: 34250702086     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01110.x     Document Type: Article

References (27)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997 349 : 1498 504.
2. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998 157 : 1418 22.
3. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987 106 : 196 220.
4. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000 55 : 114 200.
5. Anderson HR, Limb ES, Bland JM, Ponce de Leon A, Strachan DP et al. Health effects of an air pollution episode in London, December 1991. Thorax 1995 50 : 1188 93.
6. Donaldson GC, Seemungal T, Jeffries DJ, Wedzicha JA. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur. Respir. J. 1999 13 : 844 9.
7. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997 52 : 67 71.
8. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 1996 154 : 959 67.
9. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur. Respir. J. 1995 8 : 1398 420.
10. Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet 1998 352 : 467 73.
11. Heggestad T, Lilleeng SE. Measuring re-admissions: focus on the time factor. Int. J. Qual. Health Care 2003 15 : 147 54.
12. Garcia-Aymerich J, Monso E, Marrades RM, Escarrabill J, Felez MA et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am. J. Respir. Crit. Care Med. 2001 164 : 1002 7.
13. Garcia-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morera J et al. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur. Respir. J. 2000 16 : 1037 42.
14. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: national heart, lung, and blood institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): workshop summary. Am. J. Respir. Crit. Care Med. 2001 163 : 1256 76.
15. Fletcher CM, Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959 2 : 257 66.
16. Mahler D, Wells C. Evaluation of clinical methods for rating dysnea. Chest 1988 93 : 580 6.
17. Quanjer PH, Tammeling GJ, Cotes JE, Fabbri LM, Matthys H et al. Standardized lung function testing: lung volumes and forced ventilatory flows. Eur. Respir. J. 1993 6 (Suppl. 16 5 40.
18. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 2001 163 : 1256 76.
19. Garcia-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM et al. Risk factors of re-admission to hospital for a COPD exacerbation: a prospective study. Thorax 2003 58 : 100 5.
20. Almagro P, Barreiro B, Ochoa de Echaguen A, Quintana S, Rodriguez Carballeria M et al. Risk factors for hospital re-admission in patients with chronic obstructive pulmonary disease. Respiration 2006 73 : 311 7.
21. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004 350 : 1005 12.
22. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am. J. Respir. Crit. Care Med. 2003 167 : 544 9.
23. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann. Intern. Med. 1991 114 : 216 23.
24. Schols AM, Wesseling G, Kester AD, de Vries G, Mostert R et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur. Respir. J. 2001 17 : 337 42.
25. Davies L, Nisar M, Pearson MG, Costello RW, Earis JE et al. Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease. Q. J. Med. 1999 92 : 395 400.
26. Weir DC, Burge PS. Effects of high dose inhaled beclomethasone dipropionate, 750 μg and 1500 μg twice daily and 40mg per day oral prednisolone on lung function, symptoms and bronchial hyper-reactivity in patients with non-asthmatic chronic airflow obstruction. Thorax 1993 48 : 309 16.
27. Wempe JB, Postma DS, Breederveld N, Alting-Hebing D, van der Mark TW et al. Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma. J. Allergy Clin. Immunol. 1992 89 : 679 87.